Pregnancy outcomes following first trimester exposure to semaglutide.
Obstet Med · 2025
Last updated 2026-08-28| Journal | Obstet Med, 2025 |
|---|---|
| Citations | 14 |
| Relative citation ratio | 4.77 |
| Molecules | semaglutide |
Abstract
BACKGROUND AND OBJECTIVE: To review pregnancy outcomes in women exposed to semaglutide during early pregnancy.
METHODS: A retrospective review of an obstetric database at a tertiary obstetric hospital in Brisbane, Australia.
RESULTS: Thirteen women were exposed to semaglutide in first trimester. One infant had significant cardiac anomalies in the setting of very poor maternal glycaemic control in first trimester, as well as maternal obesity and hypertension.
CONCLUSION: This study adds to the growing literature suggesting there is no increased risk of major congenital anomalies following first trimester exposure to semaglutide, however, until larger studies are available to confirm these findings, reproductive-age women using semaglutide should practice effective contraceptive methods. Preconception counselling of all women with diabetes mellitus is critical to avoid adverse pregnancy outcomes.
Verbatim abstract via PubMed 40487375 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.